2025 Obesity Drug Research: What the Evidence Shows

The landscape of obesity medicine has changed dramatically over the past decade, and clinicians, patients, and policymakers are struggling to keep pace. A sweeping new systematic review and network meta-analysis published in The BMJ in 2025 offers what may be the most comprehensive head-to-head comparison of obesity medications to date — and the findings are both encouraging and sobering. For anyone navigating the crowded field of weight-loss therapies, this study provides critical context for informed, shared decision-making.

What This Study Found

Researchers led by Nong and colleagues analyzed data from 262 randomized controlled trials encompassing 99,791 participants, evaluating 19 different drugs across 24 clinical outcomes. Trials ranged in follow-up duration from 12 to 172 weeks, and the team used both frequentist random-effects models and Bayesian dose-response models to assess comparative benefits and harms (Nong et al., BMJ, 2025).

When compared to lifestyle modification alone at one year, several agents demonstrated substantial weight reduction. Tirzepatide led the established medications with a mean body weight reduction of 14.9% (95% CI: −16.0% to −13.9%), followed closely by cagrilintide-semaglutide (CagriSema) at 14.8% (95% CI: −16.9% to −12.7%). Other agents showing meaningful reductions included:

• Oral semaglutide: −10.9% (95% CI: −12.7% to −9.1%)
• Orforglipron: −9.9% (95% CI: −12.4% to −7.5%)
• Subcutaneous semaglutide: −9.8% (95% CI: −10.6% to −9.1%)
• Phentermine-topiramate: −8.1% (95% CI: −9.7% to −6.5%)

The evidence quality for these findings was rated moderate to high certainty using the GRADE framework. Emerging investigational agents — including ecnoglutide, mazdutide, and retatrutide — showed potentially similar or greater reductions of 13.1–14.6%, though the certainty of evidence for these drugs was rated very low to low, meaning further research will be needed before firm conclusions can be drawn.

The study also examined body composition in detail. Tirzepatide produced the greatest reduction in fat mass (25.7%), but was also associated with the greatest reduction in lean mass (8.3%) — a finding researchers flagged as clinically relevant, particularly for older adults and individuals at risk for sarcopenia.

On the harms side, the picture was more nuanced. Discontinuation due to adverse events was highest for orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema, and oral semaglutide, with risk ratios ranging from 1.9 to 4.2. Gastrointestinal events were most pronounced with naltrexone-bupropion, oral semaglutide, orforglipron, and tirzepatide (risk ratios 3.1 to 4.2). Fatigue was notably elevated with naltrexone-bupropion (risk ratio 8.9; approximately 331 additional cases per 1,000 people over one year), orforglipron (risk ratio 3.4; 100 more per 1,000), and CagriSema (risk ratio 3.2; 92 more per 1,000).

Perhaps most notably from a cardiovascular standpoint, subcutaneous semaglutide was the only drug in the analysis associated with reduced all-cause mortality (risk ratio 0.81, 95% CI: 0.72 to 0.93) and reduced risk of myocardial infarction (risk ratio 0.72, 95% CI: 0.61 to 0.85). Both subcutaneous semaglutide and tirzepatide were associated with reduced heart failure risk. The researchers noted, however, that these cardiovascular estimates were largely informed by trials conducted in high-risk populations, which may limit how broadly these results apply.

Despite gains in weight and cardiometabolic markers, no drug convincingly improved quality of life beyond minimally important clinical differences (all mean differences less than 5 points; the accepted threshold is 10 points), a finding based on 43 trials with 45,663 participants. Similarly, no drug demonstrated a convincing reduction in kidney failure risk.

Clinical Significance

This meta-analysis reinforces a principle that experienced obesity medicine clinicians have long applied: greater efficacy often comes with greater risk. The drugs that produced the most dramatic weight loss — tirzepatide and CagriSema — were also among those with the highest rates of treatment discontinuation and adverse events. This does not make them inappropriate choices, but it does underscore the importance of individualized patient assessment.

The lean mass loss observed with tirzepatide deserves particular clinical attention. Losing muscle alongside fat can have downstream implications for metabolic health, physical function, and long-term weight maintenance. Researchers suggest this trade-off warrants further investigation, particularly in older populations or those with low baseline muscle mass.

The finding that subcutaneous semaglutide is the only agent currently demonstrating all-cause mortality reduction and cardiovascular protection adds meaningful weight to its clinical profile — though clinicians should interpret these results within the context of the high-risk cardiovascular populations in which those trials were conducted.

The quality-of-life data is a notable gap. Despite significant body weight reductions across multiple agents, the study suggests that weight loss alone may not translate into meaningful improvements in patient-reported wellbeing, at least within the timeframes studied. This highlights the need for more holistic treatment approaches that address psychological, behavioral, and social dimensions of obesity alongside pharmacotherapy.

Current Access and Compliance Context

While the clinical evidence for several of these agents is robust, real-world access remains inconsistent. Supply shortages, high out-of-pocket costs, and variable insurance coverage continue to create barriers for patients who may benefit most. For subcutaneous semaglutide and tirzepatide in particular — the two agents with the strongest overall evidence profiles in this meta-analysis — cost and formulary restrictions remain significant obstacles in many health systems.

Emerging oral formulations, such as oral semaglutide and the investigational orforglipron, may eventually improve adherence for patients who are averse to injections. However, the data in this meta-analysis suggests that oral agents carry their own tolerability challenges, particularly with respect to gastrointestinal side effects and fatigue.

Compounded versions of semaglutide and tirzepatide have proliferated during shortage periods, though these preparations fall outside the regulatory oversight applied to FDA-approved products. Patients and clinicians should weigh these considerations carefully when evaluating treatment options.

What Patients Should Know

If you or someone you care for is considering pharmacotherapy for obesity or overweight, this research offers several important takeaways:

• No single drug is right for everyone. The best medication depends on your individual health history, cardiovascular risk profile, tolerability, and treatment goals.
• Bigger weight loss doesn't always mean better overall outcomes. Some of the most effective weight-loss drugs also carry the highest rates of side effects and treatment discontinuation.
• Muscle loss is a real concern. The study suggests that some agents, particularly tirzepatide, may reduce lean mass alongside fat — something worth discussing with your healthcare provider, especially if you are older or physically inactive.
• Cardiovascular benefits are not universal. Currently, only subcutaneous semaglutide has demonstrated reductions in all-cause mortality and heart attack risk in clinical trials, and primarily in high-risk populations.
• Quality of life may not improve automatically. The research found that weight loss from these medications did not consistently produce meaningful improvements in quality-of-life scores, suggesting that comprehensive care — including behavioral support — remains important.
• Side effects are common and should be monitored. Gastrointestinal symptoms and fatigue affect a meaningful proportion of patients on these therapies. Open communication with your provider about what you're experiencing is essential.

Conclusion

This landmark BMJ network meta-analysis represents one of the most thorough comparative assessments of obesity pharmacotherapy ever conducted. Its central message is both empowering and cautionary: effective options exist, but every treatment involves trade-offs. The study's authors emphasize that decisions should be made collaboratively between patients and clinicians, grounded in individual risk-benefit assessment and shared decision-making.

If you are looking for a qualified healthcare provider who is knowledgeable about evidence-based obesity treatments and peptide-based therapies, the Peptide Association's physician directory is a trusted starting point. Visit peptideassociation.org/find-a-doctor to connect with a clinician in your area.

---

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The information presented is based on published peer-reviewed research and is provided to support informed conversations between patients and their healthcare providers. Always consult a qualified medical professional before starting, stopping, or changing any medication or treatment plan.

---

Citation (AMA format): Nong K, Shi Q, Xie X, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2025. doi:10.1136/bmj-2026-372161. PMID: 42419792.